Estrogen directly attenuates human osteoclastogenesis, but has no effect on resorption by mature osteoclasts

DNA and Cell Biology

Volumn 25, Issue 8, 2006, Pages 475-483

  Sorensen M G ^a   Henriksen, K ^a   Dziegiel, M H ^b   Tanko L B ^a   Karsdal, M A ^a  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b Mental Health Services CPH   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CARBOXY TERMINAL CROSSLINKED TELOPEPTIDE; CD14 ANTIGEN; COLONY STIMULATING FACTOR 1; CYTOKINE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; OSTEOCLAST DIFFERENTIATION FACTOR; TELOPEPTIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; CELL MATURATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME ACTIVITY; ESTROGEN DEFICIENCY; FEMALE; GENE EXPRESSION; HORMONE SUBSTITUTION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MENOPAUSE; MONOCYTE; NORMAL HUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN SECRETION; WESTERN BLOTTING;

BLOTTING, WESTERN; BONE RESORPTION; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; HUMANS; IMMUNOHISTOCHEMISTRY; OSTEOCLASTS;

EID: 33747592377     PISSN: 10445498     EISSN: None     Source Type: Journal    
DOI: 10.1089/dna.2006.25.475     Document Type: Article

References (47)

1. BATRA, G.S., HAINEY, L., FREEMONT, A.J., ANDREW, G., SAUNDERS, P.T., HOYLAND, J.A., and BRAIDMAN, I.P. (2003). Evidence for cell-specific changes with age in expression of oestrogen receptor (ER) alpha and beta in bone fractures from men and women. J. Pathol. 200, 65-73.
2. BORD, S., HORNER, A., BEAVAN, S., and COMPSTON, J. (2001). Estrogen receptors alpha and beta are differentially expressed in developing human bone. J. Clin. Endocrinol. Metab. 86, 2309-2314.
3. BRAIDMAN, I.P., HAINEY, L., BATRA, G., SELBY, P.L., SAUNDERS, P.T., and HOYLAND, J.A. (2001). Localization of estrogen receptor beta protein expression in adult human bone. J. Bone Miner. Res. 16, 214-220.
4. BURGESS, T.L., QIAN, Y., KAUFMAN, S., RING, B.D., VAN, G., CAPPARELLI, C., KELLEY, M., HSU, H., BOYLE, W.J., DUNSTAN, C.R., et al. (1999). The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J. Cell Biol. 145, 527-538.
5. CAO, Y., MORI, S., MASHIBA, T., WESTMORE, M.S., MA, L., SATO, M., AKIYAMA, T., SHI, L., KOMATSUBARA, S., MIYAMOTO, K., et al. (2002). Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats. J. Bone Miner. Res. 17, 2237-2246.
6. COMPSTON, J.E. (2001). Sex steroids and bone. Physiol. Rev. 81, 419-447.
7. DRAKE, F.H., DODDS, R.A., JAMES, I.E., CONNOR, J.R., DEBOUCK, C., RICHARDSON, S., LEE-RYKACZEWSKI, E., COLEMAN, L., RIEMAN, D., BARTHLOW, R., et al. (1996). Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. J. Biol. Chem. 271, 12511-12516.
8. HENRIKSEN, K., GRAM, J., SCHALLER, S., DAHL, B.H., DZIEGIEL, M.H., BOLLERSLEV, J., and KARSDAL, M.A. (2004). Characterization of osteoclasts from patients harboring a G215R mutation in ClC-7 causing autosomal dominant osteopetrosis type II. Am. J. Pathol. 164, 1537-1545.
9. HENRIKSEN, K., SORENSEN, M.G., NIELSEN, R.H., GRAM, J., SCHALLER, S., DZIEGIEL, M.H., EVERTS, V., BOLLERSLEV, J., and KARSDAL, M.A. (2006). Degradation of the organic phase of bone by osteoclasts: A secondary role for lysosomal acidification. J Bone Miner. Res. 21, 58-66.
10. HUANG, W.H., LAU, A.T., DANIELS, L.L., FUJII, H., SEYDEL, U., WOOD, D.J., PAPADIMITRIOU, J.M., and ZHENG, M.H. (1998). Detection of estrogen receptor alpha, carbonic anhydrase II and tartrate-resistant acid phosphatase mRNAs in putative mononuclear osteoclast precursor cells of neonatal rats by fluorescence in situ hybridization. J. Mol. Endocrinol. 20, 211-219.
11. HUGHES, D.E., DAI, A., TIFFEE, J.C., LI, H.H., MUNDY, G.R., and BOYCE, B.F. (1996). Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat. Med. 2, 1132-1136.
12. KARSDAL, M.A., HJORTH, P., HENRIKSEN, K., KIRKEGAARD, T., NIELSEN, K.L., LOU, H., DELAISSE, J.M., and FOGED, N.T. (2003). Transforming growth factor-beta controls human osteoclastogenesis through the p38 MAPK and regulation of RANK expression. J. Biol. Chem. 278, 44975-14987.
13. KARSDAL, M.A., HENRIKSEN, K., SORENSEN, M.G., GRAM, J., SCHALLER, S., DZIEGIEL, M.H., HEEGAARD, A.M., CHRISTOPHERSEN, P., MARTIN, T.J., CHRISTIANSEN, C., et al. (2005). Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption. Am. J. Pathol. 166, 467-476.
14. KHOSLA, S. (2001). Minireview: The OPG/RANKL/RANK system. Endocrinology 142, 5050-5055.
15. KHOSLA, S., MELTON, L.J., III, and RIGGS, B.L. (2002). Clinical review 144: Estrogen and the male skeleton. J. Clin. Endocrinol. Metab. 87, 1443-1450.
16. KITAZAWA, R., KITAZAWA, S., and MAEDA, S. (1999). Promoter structure of mouse RANKL/TRANCE/OPGL/ODF gene. Biochim. Biophys. Acta 1445, 134-141.
17. KONG, Y.Y., YOSHIDA, H., SAROSI, I., TAN, H.L., TIMMS, E., CAPPARELLI, C., MORONY, S., OLIVEIRA-DOS-SANTOS, A.J., VAN, G., ITIE, A., et al. (1999). OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397, 315-323.
18. KOSTENUIK, P.J., CAPPARELLI, C., MORONY, S., ADAMU, S., SHIMAMOTO, G., SHEN, V., LACEY, D.L., and DUNSTAN, C.R. (2001). OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. Endocrinology 142, 4295-4304.
19. KREMER, M., JUDD, J., RIFKIN, B., AUSZMANN, J., and OURSLER, M.J. (1995). Estrogen modulation of osteoclast lysosomal enzyme secretion. J. Cell Biochem. 57, 271-279.
20. LACEY, D.L., TIMMS, E., TAN, H.L., KELLEY, M.J., DUNSTAN, C.R., BURGESS, T., ELLIOTT, R., COLOMBERO, A., ELLIOTT, G., SCULLY, S., et al. (1998). Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165-176.
21. LAM, J., TAKESHITA, S., BARKER, J.E., KANAGAWA, O., ROSS, F.P., and TEITELBAUM, S.L. (2000). TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest. 106, 1481-1488.
22. LEVI, G., GEOFFROY, V., PALMISANO, G., and DE VERNEJOUL, M.C. (2002). Bones, genes and fractures: workshop on the genetics of osteoporosis: From basic to clinical research. EMBO Rep. 3, 22-26.
23. LITTLEWOOD-EVANS, A., KOKUBO, T., ISHIBASHI, O., INAOKA, T., WLODARSKI, B., GALLAGHER, J.A., and BILBE, G. (1997). Localization of cathepsin K in human osteoclasts by in situ hybridization and immunohistochemistry. Bone 20, 81-86.
24. MASSEY, H.M., and FLANAGAN, A.M. (1999). Human osteoclasts derive from CD14-positive monocytes. Br. J. Haematol. 106, 167-170.
25. MICHAEL, H., HARKONEN, P.L., VAANANEN, H.K., and HENTUNEN, T.A. (2005). Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption. J. Bone Miner. Res. 20, 2224-2232.
26. NICHOLSON, G.C., MALAKELLIS, M., COLLIER, F.M., CAMERON, P.U., HOLLOWAY, W.R., GOUGH, T.J., GREGORIO-KING, C., KIRKLAND, M.A., and MYERS, D.E. (2000). Induction of osteoclasts from CD14-positive human peripheral blood mononuclear cells by receptor activator of nuclear factor kappaB ligand (RANKL). Clin. Sci. (Lond.) 99, 133-140.
27. OREFFO, R.O., KUSEC, V., VIRDI, A.S., FLANAGAN, A.M., GRANO, M., ZAMBONIN-ZALLONE, A., and TRIFFITT, J.T. (1999). Expression of estrogen receptor-alpha in cells of the osteoclastic lineage. Histochem. Cell Biol. 111, 125-133.
28. OURSLER, M.J., OSDOBY, P., PYFFEROEN, J., RIGGS, B.L., and SPELSBERG, T.C. (1991). Avian osteoclasts as estrogen target cells. Proc. Natl. Acad. Sci. USA 88, 6613-6617.
29. OURSLER, M.J., PEDERSON, L., PYFFEROEN, J., OSDOBY, P., FITZPATRICK, L., and SPELSBERG, T.C. (1993). Estrogen modulation of avian osteoclast lysosomal gene expression. Endocrinology 132, 1373-1380.
30. OURSLER, M.J., PEDERSON, L., FITZPATRICK, L., RIGGS, B.L., and SPELSBERG, T. (1994). Human giant cell tumors of the bone (osteoclastomas) are estrogen target cells. Proc. Natl. Acad. Sci. USA 91, 5227-5231.
31. PARIKKA, V., LEHENKARI, P., SASSI, M.L., HALLEEN, J., RISTELI, J., HARKONEN, P., and VAANANEN, H.K. (2001). Estrogen reduces the depth of resorption pits by disturbing the organic bone matrix degradation activity of mature osteoclasts. Endocrinology 142, 5371-5378.
32. RAMALHO, A.C., COUTTET, P., BAUDOIN, C., MORIEUX, C., GRAULET, A.M., DE VERNEJOUL, M.C., and COHEN-SOLAL, M.E. (2002). Estradiol and raloxifene decrease the formation of multinucleate cells in human bone marrow cultures. Eur. Cytokine Netw. 13, 39-45.
33. RIGGS, B.L. (2000). The mechanisms of estrogen regulation of bone resorption. J. Clin. Invest. 106, 1203-1204.
34. RIGGS, B.L., KHOSLA, S., and MELTON, L.J., III. (2002). Sex steroids and the construction and conservation of the adult skeleton. Endocr. Rev. 23, 279-302.
35. RODAN, G.A., and MARTIN, T.J. (2000). Therapeutic approaches to bone diseases. Science 289, 1508-1514.
36. RUSSELL, G., MUELLER, G., SHIPMAN, C., and CROUCHER, P. (2001). Clinical disorders of bone resorption. Novartis Found. Symp. 232, 251-267.
37. SCHLONDORFF, J., LUM, L., and BLOBEL, C.P. (2001). Biochemical and pharmacological criteria define two shedding activities for TRANCE/OPGL that are distinct from the tumor necrosis factor alpha convertase. J. Biol. Chem. 276, 14665-14674.
38. SCHOPPET, M., PREISSNER, K.T., and HOFBAUER, L.C. (2002). RANK ligand and osteoprotegerin: Paracrine regulators of bone metabolism and vascular function. Arterioscler. Thromb. Vasc. Biol. 22, 549-553.
39. SHEVDE, N.K., BENDIXEN, A.C., DIENGER, K.M., and PIKE, J.W. (2000). Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc. Natl. Acad. Sci. USA 97, 7829-7834.
40. SRIVASTAVA, S., TORALDO, G., WEITZMANN, M.N., CENCI, S., ROSS, F.P., and PACIFICI, R. (2001). Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kappa B ligand (RANKL)-induced INK activation. J. Biol. Chem. 276, 8836-8840.
41. SUNYER, T., LEWIS, J., COLLIN-OSDOBY, P., and OSDOBY, P. (1999). Estrogen's bone-protective effects may involve differential IL-1 receptor regulation in human osteoclast-like cells. J. Clin. Invest. 103, 1409-1418.
42. TEITELBAUM, S.L. (2000). Bone resorption by osteoclasts. Science 289, 1504-1508.
43. THIRUNAVUKKARASU, K., MILES, R.R., HALLADAY, D.L., YANG, X., GALVIN, R.J., CHANDRASEKHAR, S., MARTIN, T.J., and ONYIA, J.E. (2001). Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects. J. Biol. Chem. 276, 36241-36250.
44. UDAGAWA, N., TAKAHASHI, N., YASUDA, H., MIZUNO, A., ITOH, K., UENO, Y., SHINKI, T., GILLESPIE, M.T., MARTIN, T.J., HIGASHIO, K., et al. (2000). Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology 141, 3478-3484.
45. VANDERSCHUEREN, D., VANDENPUT, L., BOONEN, S., LINDBERG, M.K., BOUILLON, R., and OHLSSON, C. (2004). Androgens and bone. Endocr. Rev. 25, 389-425.
46. VIDAL, O., KINDBLOM, L.G., and OHLSSON, C. (1999). Expression and localization of estrogen receptor-beta in murine and human bone. J. Bone Miner. Res. 14, 923-929.
47. YASUDA, H., SHIMA, N., NAKAGAWA, N., MOCHIZUKI, S.I., YANO, K., FUJISE, N., SATO, Y., GOTO, M., YAMAGUCHI, K., KURIYAMA, M., et al. (1998). Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139, 1329-1337.